Join our daily newsletter At The Bell to receive exclusive market insights
- Medicinal cannabis company AusCann Group (AC8) has appointed Nick Woolf as CEO effective immediately
- Nick will be joining the company after a 25 year stint in the investment banking and life sciences industries, both in Australia and globally
- Previously, he was Chief Business Officer of Suda Pharmaceuticals (SUD), and Chief Financial Officer of PYC Therapeutics (PYC)
- After announcing his retirement in early May, previous CEO Ido Kanyon will end his time with AusCann at the end of August, after completing the handover to Nick
- AusCann is up 5.17 per cent with shares trading for 15.3 cents each
AusCann Group (AC8) has appointed Nick Woolf as CEO effective immediately.
Nick will be joining the company after a 25 year stint in the investment banking and life sciences industries, both in Australia and globally.
Previously, he was CEO of Proteolytics, Chief Business Officer of Suda Pharmaceuticals (SUD), and Chief Financial Officer of PYC Therapeutics (PYC).
“I am excited to be joining AusCann as this pivotal point in its development and building on the work already undertaken by Ido Kanyon in getting our first product into market and commencing our clinical research programs,” Nick said.
After announcing his retirement in early May, previous CEO Ido Kanyon will end his time with AusCann at the end of August, after completing the handover to Nick.
Ido joined the company more than 12 months ago from Teva Pharmaceuticals in the United States.
“We would like to thank Ido for his work leading AusCann. During his 17-month tenure with the company he completed the move to the new purpose-built facility, launched our first product into market and commenced our clinical research program,” Chairman Max Johnston said.
“He leaves behind a well-qualified team to continue the work commenced during his time,” Max said.
AusCann is up 5.17 per cent with shares trading for 15.3 cents each at 12:47 pm AEST.
